Home › Phases › Phase 3

Phase 3 (81 companies)

Companies with at least one active program at Phase 3.

Ticker	Company	Therapeutic areas	Phase 3 programs	Lead stage	Programs
FDMT	4D Molecular Therapeutics	OphthalmologyRespiratory Rare	1	Phase 3	5
ACIU	AC Immune	Neurology Rare	1	Phase 3	10
ALDX	Aldeyra Therapeutics	DermatologyOncology+1 Rare	2	NDA Submitted	7
ALT	Altimmune	GI/HepatologyMetabolic+1	1	Phase 3	3
AMLX	Amylyx Pharmaceuticals	MetabolicNeurology Rare	1	Phase 3	5
ANAB	AnaptysBio	DermatologyGI/Hepatology+2 Rare	1	Approved	6
ANNX	Annexon	HematologyNeurology+2 Rare	2	Phase 3	6
RCUS	Arcus Biosciences	DermatologyImmunology+1	3	Phase 3	6
ARDX	Ardelyx	GI/HepatologyRenal	1	Approved	4
BLTE	Belite Bio	MetabolicOphthalmology Rare	1	NDA Submitted	6
BCRX	Biocryst Pharmaceuticals	DermatologyImmunology+1 Rare	1	Approved	4
BCTX	BriaCell Therapeutics	Oncology	1	Phase 3	7
CRDL	Cardiol Therapeutics	Cardiovascular Rare	1	Phase 3	4
RNAC	Cartesian Therapeutics	ImmunologyNeurology+1 Rare	1	Phase 3	4
CLDX	Celldex Therapeutics	DermatologyImmunology+1	3	Phase 3	7
CLNN	Clene	Neurology Rare	1	Phase 3	5
CGEN	Compugen	Oncology	4	Phase 3	7
CRVS	Corvus Pharmaceuticals	DermatologyOncology	1	Phase 3	4
CRNX	Crinetics Pharmaceuticals	MetabolicOncology Rare	2	Approved	6
HELP	Cybin	Neurology	1	Phase 3	3
DFTX	Definium Therapeutics	Neurology	2	Phase 3	4
DYN	Dyne Therapeutics	MetabolicNeurology Rare	1	NDA Submitted	10
EXEL	Exelixis	CardiovascularOncology	2	Approved	22
EYPT	EyePoint	Ophthalmology	2	Phase 3	3
FBIO	Fortress Biotech	DermatologyHematology+2 Rare	1	Approved	12
GUTS	Fractyl Health	Metabolic	1	Phase 3	3
GNLX	Genelux	Oncology	1	Phase 3	3
GERN	Geron	Oncology	1	Approved	3
GOSS	Gossamer Bio	Cardiovascular Rare	2	Phase 3	4
GLSI	Greenwich LifeSciences	Oncology	1	Phase 3	1
HRMY	Harmony Biosciences	MetabolicNeurology Rare	4	Approved	17
IDYA	IDEAYA Biosciences	Oncology	1	NDA Submitted	13
IMRX	Immuneering	Oncology	1	Phase 3	5
IMUX	Immunic	GI/HepatologyNeurology	1	Phase 3	4
IMCR	Immunocore	DermatologyInfectious Disease+2	2	Approved	11
IMVT	Immunovant	ImmunologyNeurology Rare	1	Phase 3	6
INSM	Insmed	CardiovascularImmunology+2 Rare	2	Approved	17
NTLA	Intellia Therapeutics	CardiovascularImmunology Rare	2	NDA Submitted	3
IONS	Ionis Pharmaceuticals	CardiovascularHematology+5 Rare	12	Approved	29
KOD	Kodiak Sciences	Ophthalmology	6	Phase 3	8
KYTX	Kyverna Therapeutics	ImmunologyNeurology+1 Rare	1	NDA Submitted	7
MAIA	MAIA Biotechnology	Oncology	1	Phase 3	7
MIST	Milestone Pharmaceuticals	Cardiovascular	1	Approved	2
MLTX	MoonLake Immunotherapeutics	DermatologyImmunology Rare	2	Phase 3	4
NKTR	Nektar Therapeutics	DermatologyImmunology+2	1	Phase 3	11
NGNE	Neurogene	Neurology Rare	1	Phase 3	1
NAMS	NewAmsterdam Pharma	CardiovascularMetabolic+1	2	NDA Submitted	6
NRIX	Nurix Therapeutics	ImmunologyNeurology+1	1	Phase 3	16
NVCT	Nuvectis Pharma	HematologyOncology+1 Rare	2	Phase 3	8
OCGN	Ocugen	Infectious DiseaseOphthalmology Rare	4	Phase 3	12
OCS	Oculis Holding	NeurologyOphthalmology Rare	1	Phase 3	4
IRD	Opus Genetics	Ophthalmology Rare	2	Approved	12
OTLK	Outlook Therapeutics	Ophthalmology	2	Approved	3
PTN	Palatin Technologies	ImmunologyMetabolic+1 Rare	1	Phase 3	8
RLAY	Relay Therapeutics	DermatologyOncology Rare	1	NDA Submitted	5
RVPH	Reviva Pharmaceuticals	CardiovascularDermatology+2 Rare	1	Phase 3	10
RVMD	Revolution Medicines	Oncology	3	Approved	10
RYTM	Rhythm Pharmaceuticals	Metabolic Rare	5	Approved	13
SRPT	Sarepta Therapeutics	NeurologyRespiratory Rare	1	Approved	10
SLS	SELLAS Life Sciences Group	Oncology	1	Phase 3	9
SLDB	Solid Biosciences	CardiovascularNeurology Rare	1	Phase 3	6
GPCR	Structure Therapeutics	MetabolicRespiratory Rare	2	Phase 3	5
SMMT	Summit Therapeutics	Oncology	3	NDA Submitted	5
TSHA	Taysha Gene Therapies	Neurology Rare	1	Phase 3	4
TENX	Tenax Therapeutics	Cardiovascular Rare	1	Phase 3	2
TGTX	Tg Therapeutics	Neurology Rare	1	Approved	6
TVTX	Travere Therapeutics	MetabolicRenal Rare	1	Approved	7
RARE	Ultragenyx Pharmaceutical	CardiovascularGI/Hepatology+2 Rare	3	Approved	12
VNDA	Vanda Pharmaceuticals	CardiovascularDermatology+6 Rare	8	Approved	27
PCVX	Vaxcyte	Infectious Disease	2	Phase 3	6
VRCA	Verrica Pharmaceuticals	DermatologyOncology	1	Approved	3
VKTX	Viking Therapeutics	MetabolicNeurology Rare	2	Phase 3	8
VIR	Vir Biotechnology	Infectious DiseaseOncology Rare	1	Phase 3	10
VRDN	Viridian Therapeutics	ImmunologyOphthalmology	1	Approved	5
VOR	Vor Biopharma	ImmunologyNeurology Rare	2	Phase 3	2
VTVT	vTv Therapeutics	MetabolicRespiratory Rare	1	Phase 3	8
XNCR	Xencor	HematologyImmunology+4 Rare	2	Approved	36
XENE	Xenon Pharmaceuticals	Neurology Rare	3	NDA Submitted	9
ZBIO	Zenas BioPharma	DermatologyImmunology+2 Rare	2	NDA Submitted	11
ZNTL	Zentalis Pharmaceuticals	Oncology	1	Phase 3	1
ZYME	Zymeworks	OncologyRespiratory	1	Approved	11